- EXEL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $26.5 million.
- EXEL has traded 1.8 million shares today.
- EXEL is down 3.2% today.
- EXEL was up 23% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in EXEL with the Ticky from Trade-Ideas. See the FREE profile for EXEL NOW at Trade-Ideas More details on EXEL: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. Currently there are 5 analysts that rate Exelixis a buy, no analysts rate it a sell, and 3 rate it a hold. The average volume for Exelixis has been 2.9 million shares per day over the past 30 days. Exelixis has a market cap of $647.4 million and is part of the health care sector and drugs industry. The stock has a beta of 2.16 and a short float of 51% with 7.28 days to cover. Shares are down 33.3% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.